Monopar Therapeutics Inc. Operating Income
Monopar Therapeutics Inc. (MNPR) reported Operating Income of -$6.64 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-12
- Monopar Therapeutics Inc. operating income (loss) for the quarter ending 2026-06-30 was -$6.64M.
- Monopar Therapeutics Inc. operating income (loss) for the quarter ending 2026-03-31 was -$5.23M.
- Monopar Therapeutics Inc. operating income (loss) for the quarter ending 2025-12-31 was -$6.16M.
- Monopar Therapeutics Inc. operating income (loss) for the quarter ending 2025-09-30 was -$4.09M.
- Monopar Therapeutics Inc. operating income (loss) for fiscal 2025 was -$16.70M.
- Monopar Therapeutics Inc. operating income (loss) for fiscal 2024 was -$16.16M.
- Monopar Therapeutics Inc. operating income (loss) for fiscal 2023 was -$8.83M.
- Monopar Therapeutics Inc. operating income (loss) for fiscal 2022 was -$10.54M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month | Operating Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$6.64M 10-Q · filed 2026-08-12 | -$11.87M 10-Q · filed 2026-08-12 | -$18.03M derived: sum of 3 quarters · filed 2026-08-12 | -$22.12M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2026-03-31 | -$5.23M 10-Q · filed 2026-05-14 | -$11.38M derived: sum of 2 quarters · filed 2026-05-14 | -$15.47M derived: sum of 3 quarters · filed 2026-05-14 | -$18.71M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-12-31 | -$6.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$10.25M derived: sum of 2 quarters · filed 2026-03-27 | -$13.48M derived: sum of 3 quarters · filed 2026-08-12 | -$16.70M 10-K · filed 2026-03-27 | ||
| 2025-09-30 | -$4.09M 10-Q · filed 2025-11-13 | -$7.33M derived: sum of 2 quarters · filed 2026-08-12 | -$10.55M 10-Q · filed 2025-11-13 | -$21.62M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-06-30 | -$3.23M 10-Q · filed 2026-08-12 | -$6.46M 10-Q · filed 2026-08-12 | -$17.53M derived: sum of 3 quarters · filed 2026-08-12 | -$19.11M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-03-31 | -$3.22M 10-Q · filed 2026-05-14 | -$14.30M derived: sum of 2 quarters · filed 2026-05-14 | -$15.87M derived: sum of 3 quarters · filed 2026-05-14 | -$17.66M derived: sum of 4 quarters · filed 2026-05-14 | ||
| 2024-12-31 | -$11.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$12.65M derived: sum of 2 quarters · filed 2026-03-27 | -$14.44M derived: sum of 3 quarters · filed 2026-03-27 | -$16.16M 10-K · filed 2026-03-27 | ||
| 2024-09-30 | -$1.57M 10-Q · filed 2025-11-13 | -$3.36M derived: sum of 2 quarters · filed 2025-11-13 | -$5.09M 10-Q · filed 2025-11-13 | -$7.00M derived: sum of 4 quarters · filed 2025-11-13 | ||
| 2024-06-30 | -$1.79M 10-Q · filed 2025-08-12 | -$3.51M 10-Q · filed 2025-08-12 | -$5.42M derived: sum of 3 quarters · filed 2025-08-12 | -$7.49M derived: sum of 4 quarters · filed 2025-08-12 | ||
| 2024-03-31 | -$1.72M 10-Q · filed 2025-05-13 | -$3.64M derived: sum of 2 quarters · filed 2025-05-13 | -$5.70M derived: sum of 3 quarters · filed 2025-05-13 | -$8.03M derived: sum of 4 quarters · filed 2025-05-13 | ||
| 2023-12-31 | -$1.91M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$3.98M derived: sum of 2 quarters · filed 2025-03-31 | -$6.31M derived: sum of 3 quarters · filed 2025-03-31 | -$8.83M 10-K · filed 2025-03-31 | ||
| 2023-09-30 | -$2.07M 10-Q · filed 2024-11-08 | -$4.39M derived: sum of 2 quarters · filed 2024-11-08 | -$6.92M 10-Q · filed 2024-11-08 | -$9.83M derived: sum of 4 quarters · filed 2024-11-08 | ||
| 2023-06-30 | -$2.33M 10-Q · filed 2024-08-09 | -$4.85M 10-Q · filed 2024-08-09 | -$7.76M derived: sum of 3 quarters · filed 2024-08-09 | -$10.17M derived: sum of 4 quarters · filed 2024-08-09 | ||
| 2023-03-31 | -$2.53M 10-Q · filed 2024-05-09 | -$5.43M derived: sum of 2 quarters · filed 2024-05-09 | -$7.84M derived: sum of 3 quarters · filed 2024-05-09 | -$10.60M derived: sum of 4 quarters · filed 2024-05-09 | ||
| 2022-12-31 | -$2.91M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$5.32M derived: sum of 2 quarters · filed 2024-03-28 | -$8.08M derived: sum of 3 quarters · filed 2024-03-28 | -$10.54M 10-K · filed 2024-03-28 | ||
| 2022-09-30 | -$2.41M 10-Q · filed 2023-11-09 | -$5.17M derived: sum of 2 quarters · filed 2023-11-09 | -$7.63M 10-Q · filed 2023-11-09 | -$10.31M derived: sum of 4 quarters · filed 2023-11-09 | ||
| 2022-06-30 | -$2.76M 10-Q · filed 2023-08-10 | -$5.22M 10-Q · filed 2023-08-10 | -$7.90M derived: sum of 3 quarters · filed 2023-08-10 | -$10.36M derived: sum of 4 quarters · filed 2023-08-10 | ||
| 2022-03-31 | -$2.46M 10-Q · filed 2023-05-11 | -$5.14M derived: sum of 2 quarters · filed 2023-05-11 | -$7.60M derived: sum of 3 quarters · filed 2023-05-11 | -$9.69M derived: sum of 4 quarters · filed 2023-05-11 | ||
| 2021-12-31 | -$2.68M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$5.14M derived: sum of 2 quarters · filed 2023-03-23 | -$7.23M derived: sum of 3 quarters · filed 2023-03-23 | -$9.13M 10-K · filed 2023-03-23 | ||
| 2021-09-30 | -$2.46M 10-Q · filed 2022-11-10 | -$4.55M derived: sum of 2 quarters · filed 2022-11-10 | -$6.45M 10-Q · filed 2022-11-10 | -$8.71M derived: sum of 4 quarters · filed 2022-11-10 | ||
| 2021-06-30 | -$2.09M 10-Q · filed 2022-08-11 | -$3.99M 10-Q · filed 2022-08-11 | -$6.25M derived: sum of 3 quarters · filed 2022-08-11 | -$7.90M derived: sum of 4 quarters · filed 2022-08-11 | ||
| 2021-03-31 | -$1.89M 10-Q · filed 2022-05-12 | -$4.16M derived: sum of 2 quarters · filed 2022-05-12 | -$5.80M derived: sum of 3 quarters · filed 2022-05-12 | -$7.27M derived: sum of 4 quarters · filed 2022-05-12 | ||
| 2020-12-31 | -$2.26M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | -$3.91M derived: sum of 2 quarters · filed 2022-03-24 | -$5.37M derived: sum of 3 quarters · filed 2022-03-24 | -$6.51M 10-K · filed 2022-03-24 | ||
| 2020-09-30 | -$1.65M 10-Q · filed 2021-11-12 | -$3.11M derived: sum of 2 quarters · filed 2021-11-12 | -$4.25M 10-Q · filed 2021-11-12 | -$5.47M derived: sum of 4 quarters · filed 2021-11-12 | ||
| 2020-06-30 | -$1.46M 10-Q · filed 2021-08-12 | -$2.60M 10-Q · filed 2021-08-12 | -$3.83M derived: sum of 3 quarters · filed 2021-08-12 | -$4.58M derived: sum of 4 quarters · filed 2021-08-12 | ||
| 2020-03-31 | -$1.14M 10-Q · filed 2021-05-13 | -$2.36M derived: sum of 2 quarters · filed 2021-05-13 | -$3.12M derived: sum of 3 quarters · filed 2021-05-13 | -$4.05M derived: sum of 4 quarters · filed 2021-05-13 | ||
| 2019-12-31 | -$1.22M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$1.98M derived: sum of 2 quarters · filed 2021-03-25 | -$2.92M derived: sum of 3 quarters · filed 2021-03-25 | -$4.32M 10-K · filed 2021-03-25 | ||
| 2019-09-30 | -$759.45K 10-Q · filed 2020-11-12 | -$1.69M derived: sum of 2 quarters · filed 2020-11-12 | -$3.10M 10-Q · filed 2020-11-12 | -$4.03M derived: sum of 4 quarters · filed 2020-11-12 | ||
| 2019-06-30 | -$932.11K 10-Q · filed 2020-08-06 | -$2.34M 10-Q · filed 2020-08-06 | -$3.27M derived: sum of 3 quarters · filed 2020-08-06 | -$3.93M derived: sum of 4 quarters · filed 2020-08-06 | ||
| 2019-03-31 | -$1.41M 10-Q · filed 2020-05-07 | -$2.33M derived: sum of 2 quarters · filed 2020-05-07 | -$3.00M derived: sum of 3 quarters · filed 2020-05-07 | -$3.67M derived: sum of 4 quarters · filed 2020-05-07 | ||
| 2018-12-31 | -$926.36K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | -$1.59M derived: sum of 2 quarters · filed 2020-03-27 | -$2.26M derived: sum of 3 quarters · filed 2020-03-27 | -$3.33M 10-K · filed 2020-03-27 | -$3.40M 10-K · filed 2019-02-26 | |
| 2018-09-30 | -$667.53K 10-Q · filed 2018-11-09 | -$1.34M derived: sum of 2 quarters · filed 2019-11-12 | -$2.40M 10-Q · filed 2019-11-12 | -$2.97M derived: sum of 4 quarters · filed 2019-11-12 | ||
| 2018-06-30 | -$667.53K 10-Q · filed 2019-11-12 | -$840.00K 10-Q · filed 2018-08-09 | -$1.74M 10-Q · filed 2019-08-08 | -$2.30M derived: sum of 3 quarters · filed 2019-11-12 | -$17.20M derived: sum of 4 quarters · filed 2019-11-12 | |
| 2018-03-31 | -$897.26K 10-Q · filed 2019-05-10 | -$1.63M derived: sum of 2 quarters · filed 2019-05-10 | -$16.53M derived: sum of 3 quarters · filed 2019-05-10 | -$17.13M derived: sum of 4 quarters · filed 2019-05-10 | ||
| 2017-12-31 | -$736.80K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | -$15.63M derived: sum of 2 quarters · filed 2019-02-26 | -$16.23M derived: sum of 3 quarters · filed 2019-02-26 | -$16.60M 10-K · filed 2019-02-26 | ||
| 2017-09-30 | -$14.90M 10-Q · filed 2018-11-09 | -$15.49M derived: sum of 2 quarters · filed 2018-11-09 | -$15.87M 10-Q · filed 2018-11-09 | |||
| 2017-06-30 | -$594.96K 10-Q · filed 2018-08-09 | -$968.80K 10-Q · filed 2018-08-09 | ||||
| 2017-03-31 | -$373.84K 10-Q · filed 2018-05-11 | |||||
| 2016-12-31 | -$1.19M 10-K · filed 2018-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |